On May 3, 2022 Xilis, Inc., a pioneering company developing its MicroOrganoSphere (MOS) technology to guide precision therapy for cancer patients and accelerate drug discovery and development, reported that it is participating in the recently announced public-private Oncode-PACT (Press release, Xilis, MAY 3, 2022, View Source [SID1234613429]). Led by the Netherlands-based Oncode Institute, the consortium will be supported by the National Growth Fund, an initiative of the Dutch Ministry of Economic Affairs and Climate Policy and the Ministry of Finance.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Across all cancers there remains tremendous unmet needs for new targeted treatment approaches that address the unique attributes of each patient," said Xiling Shen, PhD, Founder and Chief Executive Officer of Xilis. "Our MOS technology supports the development of new insights into tumor microenvironments and heterogeneity of the originating tumor tissue for accurate, rapid and high-throughput therapeutic profiling. Xilis is proud to be part of Oncode-PACT to help support drug discovery and development and help clinicians make more informed treatment decisions through our European-based office in Netherlands."

Xilis’ proprietary tumorsphere microencapsulation platform evaluates cancer therapies at scale and is designed to enable physicians to make precision oncology treatment decisions, identifying treatments that will led to the best response for each patient.

Alain Kummer, Managing Director Oncode Institute and Chairman of Oncode-PACT, explains: "Oncode-PACT places the patient at the center of the entire drug development chain. In the current situation, the preclinical development process is still insufficiently connected with the clinical practice, and we focus on the patient too late in the drug development process."

Oncode-PACT has the ambition to develop new demonstrably effective cancer drugs faster and more cost-effectively. The medical need is urgent, because cancer remains a leading cause of death worldwide.

On May 3, 2022 Quanterix Corporation (NASDAQ: QTRX), a company digitizing biomarker analysis with the goal of advancing the science of precision health, reported that it will release its financial results for first quarter 2022 before the start of trading on May 10, 2022 (Press release, Quanterix, MAY 3, 2022, View Source [SID1234613428]). Company management will host a conference call at 8:30 a.m. EST to discuss Quanterix’ financial results and provide a business update. The call will be hosted by Masoud Toloue, the Company’s President and Chief Executive Officer, and Michael Doyle, the Company’s Chief Financial Officer.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Individuals interested in listening to the conference call may do so by dialing (833) 686-9351 for domestic callers, or (612) 979-9890 for international callers. Please reference the following conference ID: 4589034. A live webcast will also be available at: View Source

The webcast will be available on the Company’s website, View Source, for one year following completion of the call.

To access the live webcast of Quanterix’ presentations, please visit the News & Events page within the Investors section of the Quanterix website at www.quanterix.com. Replays of the webcasts will be available on the Quanterix website for 90 days following the conference.

On May 3, 2022 Aura Biosciences Inc. (NASDAQ: AURA), a clinical-stage biotechnology company developing a novel class of virus-like drug conjugate (VDC) therapies for multiple oncology indications, reported that Elisabet de los Pinos, PhD, Chief Executive Officer of Aura will present at the 2022 Bank of America Healthcare Conference (Press release, Aura Biosciences, MAY 3, 2022, View Source [SID1234613427]). The conference is being held in Las Vegas, Nevada and the presentation will take place on Tuesday, May 10, 2022, at 4:55 p.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

A live webcast of the presentation will be available on the "Investors & Media" page under the "Events & Presentations" section of the Company’s website at View Source, where a replay of the webcast will be archived for 90 days following the presentation date.

On May 3, 2022 ADC Therapeutics SA (NYSE: ADCT), a commercial-stage biotechnology company improving the lives of those affected by cancer with its next-generation, targeted antibody drug conjugates (ADCs) for patients with hematologic malignancies and solid tumors, reported that it will host a conference call and live webcast on Monday, May 9, 2022 at 8:30 a.m. ET to report financial results for the first quarter 2022 and provide business updates (Press release, ADC BIO, MAY 3, 2022, View Source [SID1234613426]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

To access the live call, please dial 833-303-1198 (domestic) or +1 914-987-7415 (international) and provide conference ID 6928367. A live webcast of the presentation will be available under "Events and Presentations" in the Investors section of the ADC Therapeutics website at ir.adctherapeutics.com. The archived webcast will be available for 30 days following the call.

On May 3, 2022 NiKang Therapeutics Inc. ("NiKang"), a clinical stage biotech company focused on developing innovative small molecule oncology medicines to help patients with unmet medical needs and Hansoh Pharmaceutical Group Company Limited ("Hansoh Pharma", 3692.HK), a China and US based leading biopharmaceutical company, reported an exclusive collaboration and license agreement for the development and commercialization of NKT2152, for the treatment of cancer in Greater China, including Mainland China, Hong Kong, Macau and Taiwan (Press release, NiKang Therapeutics, MAY 3, 2022, View Source [SID1234613425]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"Hansoh is a leader in the development and commercialization of small molecules for the treatment of cancer in China. We are thrilled to collaborate with them to strategically advance NKT2152 and expand its reach as a potential treatment for multiple tumor types," said Zhenhai Gao, Ph.D., Co-founder, President and Chief Executive Officer of NiKang. "By combining NiKang’s precision oncology expertise with Hansoh’s proven development and commercialization capabilities in Greater China, we believe that we will be able to accelerate global development of NKT2152 and bring it as a potential novel cancer treatment to China patients sooner."

"We are excited to enter into this agreement and we look forward to working with NiKang, a leader in developing innovative small molecule oncology medicines," said Yuan Sun, Executive Director of the Board of Hansoh Pharma. "HIF2α plays an important role in the development and progression of kidney and other cancers. Based on the sound biology, excellent potency and PK profile observed in preclinical studies, we believe NKT2152 has the potential to become a best-in-class molecule to address this important pathway. Our extensive expertise in oncology drug development can help accelerate development and advance NKT2152 as quickly as possible for cancer patients in China."

Under the terms of the agreement, NiKang will receive an upfront cash payment of $15 million and will be eligible to receive up to $203 million in potential development, regulatory and sales-based milestone payments, and tiered royalties. Hansoh will be responsible for all the development costs for NKT2152 in Greater China and will receive the exclusive rights to develop and commercialize NKT2152 in the region.

About NKT2152

NKT2152 is a small molecule that inhibits HIF2α. It is currently in a phase 1/2 dose escalation and expansion trial (NCT05119335). This trial is designed to evaluate safety, tolerability, pharmacokinetics, pharmacodynamics and clinical activity in patients with advanced ccRCC.